[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-377706-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-377706-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","cart-cell-therapy-for-the-management-of-mantle-cell-lymphoma-review","CART-Cell therapy for the management of mantle cell lymphoma - review","","Mantle cell lymphoma (MCL) is an incurable subtype of non-Hodgkin lymphoma of mature B-cells, driven by translocation and characteristic Cyclin D1 overexpression. Prognosis worsens with advanced age, male sex, rapid progression, extensive nodal disease, high lactate dehydrogenase, elevated Ki-67, and TP53 mutations. CAR-T immunotherapy targeting B-cell surface antigens is promising for relapsed/refractory MCL. Brexucabtagene autoleucel (Tecartus, KTE-X19) is approved based on ZUMA-2 trial outcomes, while adverse reactions and tumor escape, limited infiltration, and trafficking remain barriers.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cart-cell-therapy-for-the-management-of-mantle-cell-lymphoma-review/377706/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cart-cell-therapy-for-the-management-of-mantle-cell-lymphoma-review/377706.png","ImageObject",300,407,{"name":42,"@type":43},"Olivia Brown","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-09-27","2026-09-24",true,{"@type":52,"interactionType":53,"userInteractionCount":30},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"What characterizes mantle cell lymphoma (MCL)?","Question",{"text":62,"@type":63},"MCL is a mature B-cell subtype of non-Hodgkin lymphoma marked by translocation, typically leading to excess Cyclin D1 expression. It has a varied course and remains incurable despite treatment advances.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"Which factors indicate a poor prognosis in MCL?",{"text":67,"@type":63},"Poor outcome is associated with older age, male gender, rapid advancement, significant nodal involvement, elevated serum lactate dehydrogenase, higher Ki-67 expression, and TP53 mutation.",{"name":69,"@type":60,"acceptedAnswer":70},"Why is CAR-T cell therapy considered for MCL and what are its key challenges?",{"text":71,"@type":63},"CAR-T therapy is advantageous for B-cell malignancies by targeting B-cell antigens on tumor cell surfaces, which is feasible in relapsed/refractory MCL. Major barriers include serious adverse reactions, limited anti-tumor activity, allergen withdrawal, antigen escape, limited tumor infiltration, and trafficking issues.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},377706,1790318988,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,109,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":107,"slug":108},7,40,"healthcare",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},8,"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":106,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":30,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":127,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Huang et al. Molecular Cancer (2023) 22:67 [https://doi.org/10.1186/s12943-023-01755-5](https://doi.org/10.1186/s12943-023-01755-5)  \nMolecular Cancer  \n REVIEW Open Access  \nCART-Cell therapy for the management of mantle cell lymphoma  \nZoufang Huang1†, Vivek P. Chavda2*†, Rajashri Bezbaruah3, Hemant Dhamne4, Dong‑Hua Yang5 and Hong‑Bing Zhao6*  \nAbstract  \nMantle cell lymphoma (MCL) is a subtype of Non‑Hodgkin lymphoma (NHL) of mature B‑cells characterized by trans‑ location, which is typically due to excess expression of Cyclin D1 . Although with the progress in our knowledge of the causes for MCL and available treatments for MCL, this cancer is still incurable. Age, male gender, rapid advancement, significant nodal involvement, elevated serum lactate dehydrogenase level, and prognostic indications including increased expression of Ki‑67 and presence ofTP53 mutation, are symbols of poor outcome. Advanced immunother‑ apy using chimeric antigen receptor (CAR)‑T cells is advantageous for patients suffering from B‑cell malignancies and MCL. Targeting B‑cell antigens on the cell surface is a feasible approach in re‑occurring (R/R) MCL because of signifi‑ cant responses obtained in other B‑cell cancers. USFDA has approved brexucabtagene autoleucel (Tecartus, KTE‑X19), a novel CART‑cell therapy to be used in patients with MCL who have not responded to previous treatments or have relapsed. The FDA approved this new treatment depending on the outcomes ofthe ZUMA‑2 clinical trial. Serious adverse reactions, moderate anti‑tumor activity, allergen withdrawal, antigen escape, limited tumor infiltration, and trafficking are major barriers to successful CART‑cell therapy. This review is a brief synopsis of the development of CART‑cell therapy for MCL.  \nKeywords Mantle cell lymphoma, ZUMA, Brexucabtagene autoleucel, Chimeric antigen receptor T‑cell therapy  \n†Zoufang Huang and Vivek P. Chavda contributed equally to the work.  \n*Correspondence:  \nVivek P. Chavda [Vivek7chavda@gmail.com](Vivek7chavda@gmail.com)[ ](Vivek7chavda@gmail.com)Hong‑Bing Zhao [zhbzxfzzy@126.com](zhbzxfzzy@126.com)  \n1 Department of Hematology, Ganzhou Key Laboratory of Hematology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China  \n2 Department of Pharmaceutics and Pharmaceutical Technology, L M College of Pharmacy, Ahmedabad, 380009, Gujarat, India  \n3 Department of Pharmaceutical Sciences, Faculty of Science and Engineering, Dibrugarh University, Dibrugarh, India  \n4 Process Development, Gene Therapy Vector Facility, Research Management and Innvotations Directorate, King’s College London, London WC2R 2LS, UK  \n5 New York College of Traditional Chinese Medicine, Mineola, NY 11501, USA  \n6 Department of Oncology, the First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China  \nIntroduction  \nMantle cell lymphoma (MCL) is a rare class of NonHodgkin lymphoma (NHL) and has a very varied course of manifestation. The terminology ‘mantle-cell lymphoma’ was first coined by Raffeld and Jaffe in 1991 [1]. Mantle zone cells of primary lymphoid follicles are the source of this B-cell lymphoma. An outer circle of small lymphocytes encircling the germinal core of a lymphatic follicle is known as ‘mantle zone’ [2]. CD5-positive IgMproducing ‘B1a’ cells have been identified as the MCL’s probable cell of origin [3]. This neoplasm expresses a distinctive immunophenotype, such as CD5+, CD10+, Bcl-2+, Bcl-6+, CD20+, and also IgM and IgD surface immunoglobulins, which provides mature B-cells a typical morphologic appearance [4, 5] . Most of the cases have the characteristic translocation of chromosome t (11;14) (q13: q32), which leads to excessive activity of  \n© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and th","cbCaijgfhw2Yy2Vc","https://ap.wps.com/l/cbCaijgfhw2Yy2Vc","pdf",2240038,"English","# Abstract\n# Keywords\n# Introduction","[{\"question\":\"What characterizes mantle cell lymphoma (MCL)?\",\"answer\":\"MCL is a mature B-cell subtype of non-Hodgkin lymphoma marked by translocation, typically leading to excess Cyclin D1 expression. It has a varied course and remains incurable despite treatment advances.\"},{\"question\":\"Which factors indicate a poor prognosis in MCL?\",\"answer\":\"Poor outcome is associated with older age, male gender, rapid advancement, significant nodal involvement, elevated serum lactate dehydrogenase, higher Ki-67 expression, and TP53 mutation.\"},{\"question\":\"Why is CAR-T cell therapy considered for MCL and what are its key challenges?\",\"answer\":\"CAR-T therapy is advantageous for B-cell malignancies by targeting B-cell antigens on tumor cell surfaces, which is feasible in relapsed/refractory MCL. Major barriers include serious adverse reactions, limited anti-tumor activity, allergen withdrawal, antigen escape, limited tumor infiltration, and trafficking issues.\"}]","CART-Cell therapy for the management of mantle cell lymphoma - review | PDF",1790226773,48]